#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12520	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2149	578.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1409	1409	C	720	C,A	679,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12520	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2149	578.7	0	HET	.	.	.	C481T	.	481	481	C	706	706	C	716	C,T	495,172	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22172	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3539	624.4	0	.	n	.	0	T695C	SNP	695	695	T	1026	1026	C	675	C	637	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22172	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3539	624.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1668	1668	A	807	A,G	760,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22172	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3539	624.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2302	2302	C	728	C,T	678,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22172	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3539	624.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2376	2376	A	720	A	685	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22172	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3539	624.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2928	2928	C	715	C	678	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1732	folP	852	852	100.0	folP.l15.c17.ctg.1	1493	115.6	1	SNP	p	R228S	1	.	.	682	684	AGC	980	982	AGC	167;166;167	A;G;C	159;158;159	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4390	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3407	128.3	1	SNP	p	S91F	0	.	.	271	273	TCC	554	556	TCC	156;155;156	T;C,G;C	144;143,1;144	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4390	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3407	128.3	1	SNP	p	D95N	0	.	.	283	285	GAC	566	568	GAC	149;149;148	G;A;C	138;138;139	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4390	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3407	128.3	1	SNP	p	D95G	0	.	.	283	285	GAC	566	568	GAC	149;149;148	G;A;C	138;138;139	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1314	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	93.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	461	463	ACC	145;146;143	A;C;C	137;138;133	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1314	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	93.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	476	478	CAC	140;141;140	C;A;C	133;132;133	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1314	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	93.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	659	661	CAC	177;178;177	C;A;C	168;168;166	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1314	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	93.3	1	SNP	p	G45D	0	.	.	133	135	GGC	479	481	GGC	139;139;137	G;G;C	131;130;131	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	728	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1059	68.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2924	148.4	1	SNP	p	D86N	0	.	.	256	258	GAC	554	556	GAC	159;159;159	G;A;C	151;148;150	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2924	148.4	1	SNP	p	S87W	0	.	.	259	261	AGT	557	559	AGT	156;156;158	A;G;T	148;147;149	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2924	148.4	1	SNP	p	S87R	0	.	.	259	261	AGT	557	559	AGT	156;156;158	A;G;T	148;147;149	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2924	148.4	1	SNP	p	S87I	0	.	.	259	261	AGT	557	559	AGT	156;156;158	A;G;T	148;147;149	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2924	148.4	1	SNP	p	S88P	0	.	.	262	264	TCC	560	562	TCC	157;157;159	T;C,T;C	145;147,1;146	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3570	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2694	132.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1661	1663	GGC	145;147;146	G;G;C	134;134;132	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1306	1308	GCA	180;176;177	G;C;A	171;162;166	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1309	1311	ATC	177;177;178	A;T;C	170;165;171	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1321	1323	GTG	169;170;172	G;T;G	163;161;166	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1321	1323	GTG	169;170;172	G;T;G	163;161;166	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1825	1827	ACC	171;171;170	A;C;C	159;162;160	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1879	1881	GCG	158;154;156	G;C;G	140;130;139	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1879	1881	GCG	158;154;156	G;C;G	140;130;139	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2002	2004	GGC	135;134;133	G;G;C	120;120;120	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2011	2013	GGC	132;130;128	G;G;C	118;116;116	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3268	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	132.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2029	2031	CCG	114;113;112	C,G;C,G;G	91,6;90,1;89	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4640	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3166	146.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2000	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1807	110.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	577	577	C	148	C	136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	440	442	GGA	189;188;190	G;G;A	183;183;181	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	0	.	p	.	0	F135L	NONSYN	403	405	TTT	701	703	CTT	157;157;158	C;T;T	154;154;155	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	725	727	GGA	151;152;154	G;G;A	142;145;146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	0	.	p	.	0	D171G	NONSYN	511	513	GAT	809	811	GGT	172;172;174	G;G;T	161;163;159	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	0	.	p	.	0	G189S	NONSYN	565	567	GGC	863	865	AGC	164;165;164	A;G;C	155;156;155	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	929	929	T	163	T	158	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	1	SNP	p	G120K	0	.	.	358	360	GGT	656	658	GGT	156;157;156	G,A;G,A;T,G	144,1;146,1;145,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	1	SNP	p	A121N	0	.	.	361	363	GCC	659	661	GCC	157;156;155	G;C,A;C	145;144,1;146	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2200	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1577	138.8	1	SNP	p	A121D	0	.	.	361	363	GCC	659	661	GCC	157;156;155	G;C,A;C	145;144,1;146	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8560	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4853	175.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2027	2029	AAT	185;184;184	A;A;T	176;177;174	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	930	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1190	78.0	1	SNP	p	V57M	1	.	.	169	171	ATG	578	580	ATG	177;178;179	A;T;G	169;169;172	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
